HLA-B*5701 genetic screening among HIV-1 infected patients in Hong Kong: is this a practical approach in Han-Chinese?

To, Sabrina Wai-Chi; Chen, J H K; Wong, Ka-Hing; Chan, Kenny Chi-Wai; Tsang, Owen Tak‐Yin; Yam, Wing-Cheong

doi:10.1258/ijsa.2012.012102

Cited by 12 publications

(9 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Data showed that HLA-B*15:02 prevalence is high among Southeast Asians (allele frequency: 2% to 10%) but low or rare in Koreans, Japanese, and Europeans (allele frequency: 0%-1%) (31). Similar findings were also observed in the association between HLA-B*57:01 induced severe hypersensitivities (32). Therefore, this ethnic difference in the association between HLA alleles and drug-induced hypersensitivity reactions may, at least in part, be explained by the different HLA allele frequencies in different ethnic groups (33).…”

Section: Discussionsupporting

confidence: 66%

A multiplex allele‐specific real‐time polymerase chain reaction assay for HLA‐B13:01* genotyping in four Chinese populations

Liu

Chen²,

Kang

et al. 2016

HLA

View full text Add to dashboard Cite

Human leukocyte antigen HLA-B*13:01 is identified currently as a marker of individual susceptibility to drug-induced hypersensitivity reaction, such as dapsone-induced hypersensitivity reactions (DIHRs) and trichloroethylene-induced dermatitis. Therefore, screening for the HLA-B*13:01 allele can assist clinics in identifying patients at risk of developing DIHRs. By combining the allele-specific primers with TaqMan probes, we established a single tube, triplex real-time PCR to detect HLA-B*13:01. The reliability of this assay was validated by the comparison of genotyping results with those by sequence-based typing (SBT). With this assay, the distribution of HLA-B*13:01 in a total of 350 blood samples from four ethnic groups: Han, Tibetan, Uighur, and Buyei were determined. A 100% concordance was observed between the results with the established real-time PCR and SBT in 100 samples. The detection limit of this assay was 0.016 ng genomic DNA. The prevalence of HLA-B*13:01 carriers were 11%, 8%, 1%, and 2% in the Buyei (n = 100), Northern Han (n = 100), Tibetan (n = 100), and Uighur (n = 50) populations, respectively. The multiplex real-time PCR assay provided a fast and reliable method for accurate detection of HLA-B*13:01 allele prior to dapsone administration in clinical practice and onset of the reaction after exposure to trichloroethylene.

show abstract

Section: Discussionsupporting

confidence: 66%

A multiplex allele‐specific real‐time polymerase chain reaction assay for HLA‐B13:01* genotyping in four Chinese populations

Liu

Chen²,

Kang

et al. 2016

HLA

View full text Add to dashboard Cite

show abstract

“…ABC-HSR occurs in 4%-8% of patients receiving abacavir prior to implementation of pre-emptive HLA-B*5701 testing (Hetherington et al, 2001;Mallal et al, 2008). The incidence of ABC-HSR seems to be much higher in Caucasian populations due to a higher frequency of the HLA-B*5701 allele than in non-Caucasian populations (To et al, 2013;Youssoufi et al, 2017;Agbaji et al, 2019).…”

Section: Abacavirmentioning

confidence: 99%

Diagnostic Test Criteria for HLA Genotyping to Prevent Drug Hypersensitivity Reactions: A Systematic Review of Actionable HLA Recommendations in CPIC and DPWG Guidelines

2020

View full text Add to dashboard Cite

Introduction: Certain HLA variants are associated with an increased risk of hypersensitivity reactions to specific drugs. Both the Clinical Pharmacogenetics Implementation Consortium (CPIC) and the Dutch Pharmacogenetics Working Group (DPWG) have issued actionable HLA genedrug interaction guidelines but diagnostic test criteria remain largely unknown. We present an overview of the diagnostic test criteria of the actionable HLAdrug pairs. Methods: A systematic literature search was conducted in PubMed, Embase, Web of Science and Cochrane Library. Original case-control and cohort studies were selected and sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV) and number needed to genotype (NNG) were calculated for the actionable HLA-drug pairs. Results: In general, the HLA tests show high specificity and NPV for predicting hypersensitivity reactions. The sensitivity of HLA tests shows a wide range, from 0-33% for HLA-B*1502 testing to predict lamotrigine induced SJS/TEN up to 100% for HLA-B*5701 to predict immunologically confirmed abacavir hypersensitivity syndrome (ABC-HSR). PPV is low for all tests except for HLA-B*5701 and ABC-HSR which is approximately 50%. HLA-B*5701 to predict ABC-HSR shows the lowest NNG followed by HLA-B*5801 for allopurinol induced severe cutaneous adverse drug reactions and HLA-B*1502 for carbamazepine induced SJS/TEN. Discussion: This is the first overview of diagnostic test criteria for actionable HLA-drug pairs. Studies researching HLA genes and hypersensitivity are scarce for some of the HLA-drug pairs in some populations and patient numbers in studies are small. Therefore, more research is necessary to calculate the diagnostic test criteria more accurately.

show abstract

“…Recently, the cost-effectiveness of HLA-B * 57: 01 genotyping related to prescribing abacavir has been questioned, in particular in regions and populations with low prevalence [34,35] . The cost-effectiveness of pharmacogenomic screening is influenced by many factors, with allele frequency and availability of laboratory tests being some of them.…”

Section: Discussionmentioning

confidence: 99%

High Frequency of Human Leukocyte Antigen-B*57:01 Allele Carriers among HIV-Infected Patients in Serbia

Šiljić

Salemović²,

Ćirković³

et al. 2017

Intervirology

View full text Add to dashboard Cite

Abacavir is an effective antiretroviral drug and one of the most commonly used nucleoside reverse transcriptase inhibitors in Serbia. А percentage of the treated patients experience a potentially life-threatening hypersensitivity reaction, which was shown to be associated with the presence of the class I MHC allele, HLA-B*57:01; hence genotyping for HLA-B*57:01 prior to starting abacavir is nowadays recommended in international HIV treatment guidelines. In Serbia, this testing became available in 2013. This study was designed to estimate the prevalence of the HLA-B*57:01 allele in Serbian HIV-1-infected patients. The presence of the HLA-B*57:01 allele was analyzed in 273 HIV-1-infected patients aged 18 years or more, who were abacavir naïve. Buccal swab samples were obtained from all participants and assayed for the presence of HLA-B*57:01 using a commercially available HLA-B*57:01 real-time PCR kit. The presence of the HLA-B*57:01 allele was found in 22 of 273 tested individuals (8%; 95% CI 5.4-11.9%). This is the first study that estimated the HLA-B*57:01 prevalence among HIV-infected patients in Serbia. The very high prevalence of HLA-B*57:01 found in our study strongly supports HLA-B*57:01 genotyping, which should be implemented prior to the initiation of an abacavir-containing therapy to reduce the risk of potentially life-threatening hypersensitivity reactions.

show abstract

HLA-B*5701 genetic screening among HIV-1 infected patients in Hong Kong: is this a practical approach in Han-Chinese?

Cited by 12 publications

References 0 publications

A multiplex allele‐specific real‐time polymerase chain reaction assay for HLA‐B13:01* genotyping in four Chinese populations

A multiplex allele‐specific real‐time polymerase chain reaction assay for HLA‐B13:01* genotyping in four Chinese populations

Diagnostic Test Criteria for HLA Genotyping to Prevent Drug Hypersensitivity Reactions: A Systematic Review of Actionable HLA Recommendations in CPIC and DPWG Guidelines

High Frequency of Human Leukocyte Antigen-B*57:01 Allele Carriers among HIV-Infected Patients in Serbia

Contact Info

Product

Resources

About

HLA-B*5701 genetic screening among HIV-1 infected patients in Hong Kong: is this a practical approach in Han-Chinese?

Cited by 12 publications

References 0 publications

A multiplex allele‐specific real‐time polymerase chain reaction assay for HLA‐B*13:01 genotyping in four Chinese populations

A multiplex allele‐specific real‐time polymerase chain reaction assay for HLA‐B*13:01 genotyping in four Chinese populations

Diagnostic Test Criteria for HLA Genotyping to Prevent Drug Hypersensitivity Reactions: A Systematic Review of Actionable HLA Recommendations in CPIC and DPWG Guidelines

High Frequency of Human Leukocyte Antigen-B*57:01 Allele Carriers among HIV-Infected Patients in Serbia

Contact Info

Product

Resources

About

A multiplex allele‐specific real‐time polymerase chain reaction assay for HLA‐B13:01* genotyping in four Chinese populations

A multiplex allele‐specific real‐time polymerase chain reaction assay for HLA‐B13:01* genotyping in four Chinese populations